ArticleHealth science reports2020

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.

Eric Lawitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.